- Amgen shares new Tavneos analysis in effort to resolve FDA disputeAmgen shared a new analysis with the FDA that the company said supports keeping its controversial rare disease drug Tavneos on the market. The submission, made Thursday, includes an independent r…Endpoints · 54m ago↗ source
- Ipsen’s Bylvay fails key trial in children with rare liver diseaseIpsen disclosed that Bylvay failed a Phase 3 study for biliary atresia, a serious liver disease that leads the bile ducts to become blocked in babies. Babies with the disease can get a Kasai proc…Endpoints · 3h ago↗ source
- Biogen’s Alzheimer’s data spur excitement, confusion about tau-targeting drugsLONDON — One of the most anticipated Alzheimer’s studies in the past few years has created both enthusiasm and confusion, according to conversations Endpoints News recently had with about 20 scient…